NFKB1 and B-cell chronic lymphocytic leukemia: To avoid heterogeneous responses when activating TLR signaling in CLL cells, we used a mix of TLR agonists that stimulates TLR1, TLR2, TLR6, and TLR9, and showed that it reliably triggered activation of the NF-κB and JAK-STAT signaling pathways, secretion of cytokines, and enhanced CLL cell migration and proliferation in vitro in all CLL samples, highlighting the relevance of TLR signaling in CLL pathobiology.